Year Founded
1991
Ownership
Public
Employees
~500
Therapeutic Areas
Oncology
Stage
Commercial
Modalities
Small molecule

Ariad Pharmaceuticals General Information

Iclusig (ponatinib) is a kinase inhibitor targeting BCR-ABL, including resistant mutations like T315I, and is approved for CML and Ph+ ALL in multiple regions.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States

Drug Pipeline

ponatinib
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Ariad Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Incyte Corporation

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Ariad Pharmaceuticals Funding

Deal TypeDateAmountStatusStage
Later Stage VCOct 20, 2006$14.0MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Ariad Pharmaceuticals's complete valuation and funding history, request access »